Uslu Ugur, Schliep Stefan, Schliep Klaus, Erdmann Michael, Koch Hans-Uwe, Parsch Hans, Rosenheinrich Stina, Anzengruber Doris, Bosserhoff Anja Katrin, Schuler Gerold, Schuler-Thurner Beatrice
Department of Dermatology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany
Department of Dermatology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU), Erlangen, Germany.
Anticancer Res. 2017 Sep;37(9):5033-5037. doi: 10.21873/anticanres.11918.
In patients with melanoma, early dissemination via lymphatic and hematogenous routes is frequently seen. Thus, besides clinical follow-up examination and imaging, reliable melanoma-specific serological tumor markers are needed.
We retrospectively compared two serum markers for melanoma, S100 and melanoma-inhibitory activity (MIA), for monitoring of patients with metastatic melanoma under either adjuvant or therapeutic vaccination immunotherapy with dendritic cells (DC). Serum was obtained from a total of 100 patients (28 patients in stage III and 72 patients in stage IV, according to the American Joint Committee on Cancer 2002) at regular intervals during therapy, accompanied by follow-up imaging.
When relapse was detected, both markers often remained within normal range. In contrast, in patients with metastatic measurable disease receiving therapeutic and not adjuvant DC vaccination, an increase of both markers was a strong indicator for disease progression. When comparing both markers in the whole study population, MIA showed a superior sensitivity to detect disease progression.
S100 and MIA are highly sensitive tumor markers for monitoring of patients with melanoma with current metastases, but less sensitive for monitoring of tumor-free patients. In the current study, MIA had a slightly superior sensitivity to detect progressive disease compared to S100 and seems to be more useful in monitoring of patients with metastatic melanoma receiving immunotherapy.
在黑色素瘤患者中，常可见通过淋巴和血行途径的早期播散。因此，除了临床随访检查和影像学检查外，还需要可靠的黑色素瘤特异性血清肿瘤标志物。
我们回顾性比较了两种黑色素瘤血清标志物，即S100和黑色素瘤抑制活性（MIA），用于监测接受树突状细胞（DC）辅助或治疗性疫苗免疫治疗的转移性黑色素瘤患者。在治疗期间定期从总共100例患者（根据美国癌症联合委员会2002年标准，III期28例，IV期72例）获取血清，并进行随访影像学检查。
当检测到复发时，两种标志物通常仍在正常范围内。相比之下，在接受治疗性而非辅助性DC疫苗接种的可测量转移性疾病患者中，两种标志物的升高是疾病进展的强烈指标。在整个研究人群中比较两种标志物时，MIA在检测疾病进展方面表现出更高的敏感性。
S100和MIA是监测当前有转移的黑色素瘤患者的高度敏感的肿瘤标志物，但对监测无肿瘤患者不太敏感。在本研究中，与S100相比，MIA在检测疾病进展方面敏感性略高，似乎在监测接受免疫治疗的转移性黑色素瘤患者中更有用。
